Top

Published in:

01-11-2012 | Original Paper

Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma

Authors: John Lammli, Minyan Fan, Howard G. Rosenthal, Meghan Patni, Elizabeth Rinehart, Gerardo Vergara, Elizabeth Ablah, Paul H. Wooley, George Lucas, Shang-You Yang

Published in: International Orthopaedics | Issue 11/2012

Abstract

Purpose

Osteosarcoma is the most common primary malignancy in orthopaedic surgery. Studies suggest that expression of VEGF and high vascularity within osteosarcoma may correlate with poor prognosis. The purpose of this study was to determine whether there was a correlation of VEGF expression with clinical tumour stage and metastasis.

Methods

This retrospective case series examined 54 cases of osteosarcoma patients who were treated during a ten-year period. Relevant clinical information included age, gender, tumour location, stage, adjuvant therapy, morbidity, mortality, and tumour subtypes. The clinical information was analysed for correlation of VEGF expression and tumour prognosis. Tumour sections were examined by routine H&E and by immunohistochemistry for VEGF, CD31, and the oncogenes c-myc and c-fos.

Results

There was a significantly positive correlation between VEGF expression and tumour stages among these cases (p < 0.01). The data also suggested a higher cancer recurrence and more frequent cases of remote metastasis in the high-VEGF group compared to the low-VEGF group. VEGF expression also positively associated with c-fos and c-myc expressions in the primary tumour sections.

Conclusion

The results of this study highlight the role of VEGF in angiogenesis and tumour burden. Data also suggest the influence of VEGF may associate with the elevations of c-fos and c-myc expression. The development of novel therapies to target the VEGF pathway in osteosarcoma may lead to improved survival.

Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ (2009) Osteosarcoma. J Am Acad Orthop Surg 17(8):515–527PubMed

Rosen G, Suwansirikul S, Kwon C, Tan C, Wu SJ, Beattie EJ Jr, Murphy ML (1974) High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer 33(4):1151–1163PubMedCrossRef

Coomber BL, Denton J, Sylvestre A, Kruth S (1998) Blood vessel density in canine osteosarcomas. Can J Vet Res 62(3):199–204PubMed

Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246(4935):1309–1312PubMedCrossRef

Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935):1306–1309PubMedCrossRef

Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S (2009) Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther 17(2):278–284. doi:10.1038/mt.2008.258 PubMedCrossRef

Jia ZZ, Jiang GM, Feng YL (2011) Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer. Chin Med Sci J (Chung-kuo i hsueh k'o hsueh tsa chih/Chinese Academy of Medical Sciences) 26(3):158–162

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA (2009) Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 8(7):1761–1771. doi:10.1158/1535-7163.MCT-09-0280 PubMedCrossRef

Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N, Nakamura M (1998) Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77(6):998–1002PubMedCrossRef

10.

Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC, Lee YC (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19(2):432–441PubMed

11.

Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, Fukuda H, Nakano H, Abe S, Tateishi A, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y, Nakamura M (1999) Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35(7):1089–1093PubMedCrossRef

12.

Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S (2000) Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6(2):572–577PubMed

13.

Ben Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP, Porter AT, Tang DG (1999) Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 161(3):970–976PubMedCrossRef

14.

Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1):27–31PubMedCrossRef

15.

Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143(2):401–409PubMed

16.

Weidner N, Folkman J (1996) Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 167–190

17.

Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353–364PubMedCrossRef

18.

McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5(Suppl 1):3–10PubMedCrossRef

19.

Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16):15–18PubMed

20.

Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K, Kamada T (1996) Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56(13):3004–3009PubMed

21.

Cole MD, McMahon SB (1999) The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 18(19):2916–2924PubMedCrossRef

22.

van den Berg S, Rahmsdorf HJ, Herrlich P, Kaina B (1993) Overexpression of c-fos increases recombination frequency in human osteosarcoma cells. Carcinogenesis 14(5):925–928PubMedCrossRef

23.

Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JW, Mercola D (1990) The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5(7):989–1000PubMed

24.

Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Sollazzo MR, Pompetti F, Merli M, Magagnoli G, Balladelli A, Picci P (1998) C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55(6):556–563PubMedCrossRef

25.

Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS, Carbone M (1996) Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 63(1):37–50PubMedCrossRef

26.

Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N (2000) Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 60(8):2169–2177PubMed

27.

Yang SY, Yu H, Krygier JE, Wooley PH, Mott MP (2007) High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model. Sarcoma 2007:95628PubMedCrossRef

28.

Yin D, Jia T, Gong W, Yu H, Wooley PH, Mott MP, Yang SY (2008) VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol 33(2):253–259PubMed

Title: Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma
Authors: John Lammli
Minyan Fan
Howard G. Rosenthal
Meghan Patni
Elizabeth Rinehart
Gerardo Vergara
Elizabeth Ablah
Paul H. Wooley
George Lucas
Shang-You Yang
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: International Orthopaedics / Issue 11/2012
Print ISSN: 0341-2695
Electronic ISSN: 1432-5195
DOI: https://doi.org/10.1007/s00264-012-1629-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2012

Has the role of tibial interlocking nailing in closed tibial-shaft fractures diminished?

Cysteine-rich matricellular protein improves callus regenerate in a rabbit trauma model

The Locking Compression Paediatric Hip Plate™: technical guide and critical analysis

Tip apex distance, hip screw placement, and neck shaft angle as potential risk factors for cut-out failure of hip screws after surgical treatment of intertrochanteric fractures

A safe technique of anterior column lag screw fixation in acetabular fractures

Application and survival curve of total hip arthroplasties: a systematic comparative analysis using worldwide hip arthroplasty registers